Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
It's which option, if any, aligns with a specific patient's medical profile, lifestyle, and goals under the guidance of a licensed clinician
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
There is also the constipation factor
~ AlphaMD Hormonal imbalances can significantly impact your energy, mood, focus, and overall well-being
1 Data like this is important because it determines whether these drugs should be looked at as a permanent aspect of a patients lifestyle or something that kickstarts a weight-loss phase
